OneSource Specialty Pharma Reports Strong Q4 Results, Consolidates Singapore Operations to Fuel Global Growth

OneSource Specialty Pharma Ltd, a fast-growing contract development and manufacturing organization (CDMO), reported robust financial performance for the March 2025 quarter and announced strategic consolidation of its Singapore business operations. The step is part of the company's overall strategy to rationalize its global presence and leverage growing demand for specialty pharma and biologics solutions.

 

Key Highlights

 

Robust Q4 Financial Performance:

For the quarter ended March 31, 2025, OneSource Specialty Pharma reported consolidated revenue from operations of ₹4.26 billion and a consolidated profit of ₹985 million. This is a noteworthy improvement compared to past years, demonstrating the company's operational efficiency and effective integration of its merged business segments.

 

Singapore Operations Consolidation:

The Board has sanctioned the consolidation of all Singapore business operations into a single structure. This strategic initiative is intended to minimize complexity, improve supply chain efficiency, and deliver seamless service to global clients, especially in regulated markets like the US, Europe, and Australia.

 

Rapid Growth Trajectory

OneSource is expected to record 32% revenue growth in 2025, with sales reaching $400 million by 2028. Growth for the company is being spurred by increasing demand for drug-device combinations, biologics, and self-administered therapies, particularly GLP-1s, and by regulatory changes such as the Biosecure Act that are spurring supply chain diversification.

 

Integrated Global Platform:

Established through the merger of Stelis Biologics CDMO, SteriScience's Complex Injectables, and Strides' Soft Gelatin businesses, OneSource currently has five world-class manufacturing facilities, including a flagship facility in Bangalore with an ability to produce both biologics drug substances as well as drug products. The company is able to produce more than 100 million doses of injectables and 2.4 billion soft gelatin capsules every year.

 

Operational and Financial Strength:

Improved leverage ratios and interest cover were reported by the company, with gearing overall anticipated to be moderate at 2.5x as of March 2025. Improved EBITDA margins and profitability reflect OneSource's success in creating value for stakeholders and investing in growth.

 

Leadership Commentary:

CEO Neeraj Sharma noted the company's "impressive new business wins and strong Q4 results," citing OneSource's focus on being the top Indian CDMO globally.

 

Outlook

With the integration of Singapore operations and ongoing investment in advanced manufacturing, OneSource Specialty Pharma is well-placed to benefit from expanding demand in the global pharmaceutical outsourcing market. Its integrated model, regulatory approvals, and emphasis on innovation are anticipated to propel long-term revenue and profit growth in the years ahead.

 

Source: NSE Corporate Filings, CHEManager, Screener, CARE Ratings, ICICI Direct